JAK1 and myeloproliferative disorder: NGS profiling along with SNP array karyotyping at several stages of disease progression revealed that clonal evolution was not halted but continued despite intermittent targeted inhibition of JAK2 signaling via the JAK1/2 inhibitor ruxolitinib, as has been reported for the classical, Philadelphia chromosome-negative MPN [26].